Cancer and Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America

1st Edition, Volume 46-3 - July 10, 2020
Editor: John Davis
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 1 2 6 - 0
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 6 1 2 7 - 7

This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series… Read more

Cancer and Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren’s Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.

Cover image
Title page
Table of Contents
Copyright
Contributors
Rheumatic Disease Clinics of North America
Foreword
Preface
Overview of the Associations Between Cancer and Rheumatic Disease
Key points
Introduction
Overview of the associations between cancer and rheumatic disease
Overview of shared risk factors
Potential causal pathways from cancer to rheumatic disease
Drug effects, cancer, and rheumatic disease
Summary
Clinics care points
Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms
Key points
Introduction
Rheumatologic association with myeloid neoplasms
Summary
Clinics Care Points
Cancer and Rheumatoid Arthritis
Key points
Cancer risk in rheumatoid arthritis
Cancer risk in rheumatoid arthritis in association with use of antirheumatic drugs
Cancer screening in patients with cancer
Safety of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and prior or concomitant cancer
Recommendations on the management of rheumatoid arthritis in patients with cancer
Use of corticosteroids in patients with rheumatoid arthritis and cancer
Cancer treatment in patients with rheumatoid arthritis
Summary
Clinics care points
Risk of Malignancy in Spondyloarthritis: A Systematic Review
Key points
Introduction
Methods
Risk for malignancy in psoriatic arthritis
Risk of malignancy in ankylosing spondylitis
Cancer and spondyloarthritis (combined axial spondyloarthritis and psoriatic arthritis)
Association of pharmacotherapies for spondyloarthritis with cancer
Risk of malignancy following therapeutics in spondyloarthritis with prior malignancy
Other risk factors for cancer in spondyloarthritis
Spondyloarthritis and cancer screening
Considerations in interpretation of available data
Clinics care points
Summary
Sjögren Syndrome and Cancer
Key points
General considerations
Mucosa-associated lymphoid tissue lymphoma
Other lymphomas and leukemias
Multiple myeloma
Lung cancer
Thymus masses
Skin cancer
Other cancers, including breast
Sarcoma
Cancer therapy and Sjögren syndrome
Summary
Clinics Care Points
Supplemental Table 1. Comparison of standardized incidence ratios for overall malignancy incidence in patients with Sjögren syndrome
Supplemental Table 2. Studies of nonlymphoma malignancy in Sjögren syndrome
Cancer and Systemic Lupus Erythematosus
Key points
Introduction
Hematologic cancers
Lung cancers
Cervical and vulvar cancers
Other cancers with increased risk
Decreased cancer risk in systemic lupus erythematosus
Summary
Clinics care points
Cancer and Scleroderma
Key points
Epidemiology of cancer in patients with scleroderma
Potential mechanisms linking cancer and scleroderma
Unique autoantibodies identify patient subgroups with a high risk of cancer-associated scleroderma
Evidence for a model of cancer-induced autoimmunity
Cancer protective immune responses may modify cancer risk in scleroderma
Implications for cancer screening
Summary
Clinics care points
Risk Factors and Cancer Screening in Myositis
Key points
Introduction
Definition and timing of cancer-associated myositis
Clinical and serologic risk factors for cancer associated myositis
Serologic risk factors for cancer-associated myositis
Proposed risk stratification based on myositis autoantibodies
Screening strategies
Approach to screening
Summary
Clinics care points
Paraneoplastic Musculoskeletal Syndromes
Key points
Introduction
Specific paraneoplastic syndromes
Summary
Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity
Key points
Introduction
Immune-related adverse events
Rheumatic immune-related adverse events
Common rheumatic immune-related adverse events
Life-threatening rheumatic immune-related adverse events
Immune checkpoints—mechanism of action
Cytotoxic T-lymphocyte–associated protein 4 and programmed death 1 and autoimmunity
Summary